An omicron-based vaccine booster elicits potent neutralizing antibodies against emerging SARS-CoV-2 variants in adults

SARS-CoV-2 Omicron subvariants have become the predominantly strain in most countries. However, the neutralizing activity of the human serum after Omicron-based vaccine booster against different SARS-CoV-2 variants is poorly understood. Here, we developed an update Omicron vaccine (SCoK-Omicron), ba...

Full description

Saved in:
Bibliographic Details
Published inEmerging microbes & infections Vol. 12; no. 1; p. 2207670
Main Authors Li, Tao, Luo, Deyan, Ning, Nianzhi, Wang, Xin, Zhang, Liangyan, Yang, Xiaolan, Li, Deyu, Sun, Yakun, Yu, Wenjing, Wei, Wenjin, Wang, Hui
Format Journal Article
LanguageEnglish
Published United States Taylor & Francis 01.12.2023
Taylor & Francis Ltd
Taylor & Francis Group
Subjects
Adult
Antibodies, Neutralizing
Antibodies, Viral
booster
Coronaviruses
COVID-19 - prevention & control
Humans
Letter
Mutation
neutralizing titers
Omicron
SARS-CoV-2
SARS-CoV-2 - genetics
Severe acute respiratory syndrome coronavirus 2
vaccine
Vaccines
SARS-CoV-2
vaccine
Omicron
neutralizing titers
booster
Online AccessGet full text

Cover

More Information
Summary:SARS-CoV-2 Omicron subvariants have become the predominantly strain in most countries. However, the neutralizing activity of the human serum after Omicron-based vaccine booster against different SARS-CoV-2 variants is poorly understood. Here, we developed an update Omicron vaccine (SCoK-Omicron), based on the RBD-Fc fusion protein vaccine (SCoK) and RBD domain of Omicron BA.1. To assess cross-variant neutralizing activity in adults, 25 volunteers that have received three doses of SCoK and 25 volunteers with two doses of CoronaVac (inactive vaccine) were further boosted with a dose updated vaccine (SCoK-Omicron). The results of pseudovirus neutralization assays demonstrated that the booster potently induced the high-level of neutralizing antibody against SARS-CoV-2 Wild type, Delta and Omicron subvariants in adults. Further assays of single point mutations showed that K444T, L452R, N460K, or F486V was key mutations to cause immune evasion. Together, these data suggest that SCOK-Omicron can be used as a booster vaccine candidate in adults receiving subunit protein or inactivated vaccine in response to the epidemic of COVID-19 Omicron subvariants, and the mutation K444T, L452R, N460K, or F486V needs to be considered in future vaccine design.
Bibliography:SourceType-Other Sources-1
content type line 63
ObjectType-Correspondence-1
These authors contributed equally to this article.
Supplemental data for this article can be accessed online at https://doi.org/10.1080/22221751.2023.2207670.
ISSN:2222-1751
2222-1751
DOI:10.1080/22221751.2023.2207670